To determine the efficacy and safety of triclosan-impregnated sutures. Background: Surgical-site infections (SSIs) produce considerable morbidity and increase health care costs. A potential strategy to decrease the rates of SSIs may be the use of triclosan-impregnated sutures. These have been endorsed and/or funded by professional and governmental bodies in numerous countries. Laboratory studies and nonsystematic reviews have suggested that these sutures may reduce SSIs but there has been no summative assessment of this intervention with regard to clinical efficacy and safety. Hence, a systematic review and meta-analysis of all randomized controlled trials (RCTs) investigating triclosan-impregnated sutures were conducted. Methods: The Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Pubmed databases, and trial registries were searched for published and unpublished RCTs. The endpoints of interest were the incidence of SSIs and wound breakdown. A random effects model was used and pooled estimates were reported as odds ratios (ORs) with the corresponding 95% confidence interval (CI). Results: Seven RCTs encompassing a total of 836 patients were included in the final analysis. The studies were of moderate quality. Triclosan-impregnated sutures did not statistically significantly reduce the rates of SSIs (OR = 0.77; 95% CI: 0.40-1.51; P = 0.45; I 2 = 24%). There was no difference in the rates of wound breakdown between the 2 groups (OR = 1.07; 95% CI: 0.21-5.43; P = 0.93; I 2 = 44%) Conclusions: Triclosan-impregnated sutures do not decrease the rate of SSIs or decrease the rate of wound breakdown. Further high-quality independent studies within the right context are required before routine clinical use can be considered. (Ann Surg 2012;255:854-859) S urgical site infections (SSIs) represent a major problem for patients, clinicians, and the health service. The overall incidence of SSIs is conservatively estimated to be 2% to 5% and accounts for about 20% of all health care-associated infections. 1,2 SSIs increase morbidity and mortality as well as impose a financial burden by increasing the cost per case for orthopedic and cardiac surgery by an average of $30,000 and $60,000, respectively. [2] [3] [4] [5] [6] The actual cost of SSIs may even be higher due to underreporting. Furthermore, the costs of outpatient management in the community are often not addressed in many studies. 6 Apart from the financial cost, other consequences for the patient such as pain, reduced quality of life, time off work, and loss of productivity are difficult to quantify.
In the United States, the incidence of SSIs is considered to be a proxy measure of performance and has led to inevitable comparisons between institutions with implications for financial reimbursement. 3, [7] [8] [9] [10] As of 2008, the Centers for Medicare and Medicaid Services began to withhold payment for treatment of SSI after certain bariatric, cardiac, and orthopedic procedures. 11 The National Institute for Health and Clinical Excellence and The Infectious Diseases Society of America as part of the Surgical Care Improvement Project have each published guidelines pertaining to SSIs, made after an extensive literature review and wide consultation. 12, 13 As a result, there has been a renewed emphasis on strategies to reduce SSIs. 1 The causes of SSIs are multifactorial, but, crucially, SSIs are preventable. 1, 14 One important factor in the development of SSI is bacterial colonization of suture material, especially on braided sutures and around suture knots. 15 Microorganisms colonize the suture as it is passed through human tissue in the surgical wound, which then forms a "biofilm" that confers immunity from antimicrobial treatment and the immune system. 16 Once a biofilm is established, it is difficult to remove the organism and this potentiates the risk of developing an SSI. In a model of wound infection proposed by Elek and Conen, 17 a small amount of innoculum has been shown to be sufficient to cause infection in the presence of foreign material (suture). Hence, the idea of imbuing sutures with antibacterial properties was a logical extension to minimize this risk. However, since the first publication in the 1940s, there has been little development and application of this concept into the actual clinical practice. 18 Recently, an antimicrobial agent, Triclosan, has been used to imbue sutures with antibacterial properties, and Triclosanimpregnated Polyglactin 910 (Vicryl Plus, Ethicon Inc, NJ) received approval from the Food and Drug Administration in America in 2002. 19 Triclosan has been used in a variety of pharmaceutical products for its antiseptic properties over the past 30 years and has an established safety profile and broad-spectrum activity against common pathogens responsible for SSIs including resistant strains. 20, 21 Despite an absence of level 1 evidence, recent publications from expert panels have shown great interest in these sutures. 12,22,23 Their efficacy remains unproven and there are concerns regarding the safety of these sutures as one trial had shown an increased risk of wound dehiscence. 24 Therefore, we conducted a systematic review and metaanalysis of all randomized controlled trials (RCTs) to evaluate the clinical efficacy and safety of triclosan-impregnated sutures.
METHODS

Study Identification
Medline , EMBASE (1947 EMBASE ( -2010 , and Web of Science to identify published and unpublished RCTs as well as abstracts from recent scientific meetings. Additional searches were performed at multiple trial registries to identify unpublished clinical trials. 27, 28 
Study Selection and Validity Assessment
Only RCTs that evaluated the clinical efficacy and safety of triclosan-impregnated sutures were included. The exclusion criteria were in vitro experiments, animal studies, studies with cointerventions, or studies that were not RCTs. Studies were considered for inclusion by 2 authors (W.K.C., S.S.) with any disagreements resolved by discussion with senior authors (R.P.M., A.G.H.). The methodological quality of the included studies was assessed according to the criteria specified by the Cochrane Collaboration and risk of bias summary figures were generated. 25
Data Abstraction
The 2 outcomes of interest were the incidence of SSIs and wound breakdown as a proxy for wound healing. Wound breakdown was defined a priori as spontaneous disruption or separation of the wound with or without infection. This included fascial dehiscence when the sutures were used to approximate fascia. The outcomes were counted as per event and assumed as defined if reported. Missing information as well as information regarding unpublished trials was obtained through corresponding authors who were contacted twice via e-mail over a period of 1 month. If there was no response at the end of month, the study was excluded for the specific outcome but still included in other analyses where data were available.
Statistical Analysis
The data analysis was performed using Revman 5.0 (Review Manager 5.0, Copenhagen, Denmark: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008). A random effects model was used, and the odds ratio (OR) for each study was aggregated to obtain a pooled OR with a corresponding 95% confidence interval (CI). Study heterogeneity was assessed using the I 2 statistic and the χ 2 test for heterogeneity was performed, with P < 0.1 considered as statistically significant heterogeneity. I 2 values less than 25% were defined as low heterogeneity; I 2 values between 25% and 50% were considered to represent moderate heterogeneity; and values greater than 50% were defined as representing high heterogeneity. Forest plots were constructed with P < 0.05 considered to be statistically significant. A funnel plot was constructed to explore the possibility of publication bias.
RESULTS
Trial Flow
The flow of documents is as per Figure 1 . Ten papers were retrieved for full review. Seven RCTs were included in the final analysis, which included 2 unpublished trials. 24, [29] [30] [31] [32] [33] [34] Records idenƟfied through database searching (n = 407)
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Study Characteristics
The study characteristics are as per Table 1 . There were 443 patients randomized to triclosan-impregnated sutures and 393 patients randomized to conventional sutures. The summary of risk of bias assessment and funnel plot are as per Figures 2 and 3 , respectively. Overall, the included studies were of moderate quality with minimal publication bias.
Outcomes
Triclosan-impregnated sutures did not significantly decrease the rate of SSIs (OR = 0.77; 95% CI: 0.40-1.51; P = 0.45; I 2 = 24%) as shown in Figure 4 . There was no significant difference in wound breakdown between the 2 groups (OR = 1.07; 95% CI: 0.21-5.43; P = 0.93; I 2 = 44%) as shown in Figure 5 .
DISCUSSION
This study is the first level 1 evidence regarding triclosanimpregnated sutures and shows that although these sutures do not appear to have any adverse effects on wound healing, they do not reduce the incidence of SSIs.
Triclosan-impregnated sutures have shown promising results from in vitro and in vivo studies. These sutures reduce bacterial colonization in animal and in vitro studies. [35] [36] [37] [38] [39] Marco et al 40 simulated an orthopedic model of intraoperative contamination by smearing Staphylococcus epidermidis at 1 cm from a steel wire inserted into the spinous process of rats. Wound closure with triclosan-impregnated sutures resulted in 66.6% reduction in positive culture from tissue adjacent to the steel implant, thereby showing that the antibacterial influence extends to the surrounding tissue. 40 In addition, these sutures may have an immunomodulatory effect that is favorable to tissue healing as the healing factors such as hydroxyproline and transforming growth factor-β and inflammatory mediators such as tumor necrosis factor-α in contaminated wounds closed with triclosan-impregnated sutures approached that of clean wounds. 37 Previous studies by Justinger et al 41 and Fleck et al 42 have demonstrated statistically significant reductions in wound infection rates in laparotomy and sternal wounds, respectively. However, the study by Fleck et al was limited due to its retrospective nature and an unclear method of patient allocation that does not explain the significant inequality of group assignment (conventional sutures: triclosan suture = 3.7:1). Patients in the control group were also significantly older and this may represent a potential confounder as age is a recognized risk factor for SSI. 43 In Justinger et al's large retrospective study, the conclusions were limited because the study was performed over 2 time periods using 2 different sutures. In the first time period, loop PDS (polydioxanone) sutures were used to close midline laparotomy wounds, and in the subsequent period, Vicryl Plus sutures were used. Moreover, the rate of fascial dehiscence was not reported.
The results of the present study indicate that these sutures do not adversely affect wound healing. Previous studies have shown that the intraoperative handling characteristics of these sutures are similar to uncoated sutures and do not affect surgical performance. 31, 44 
Yes
No Unclear The toxicity and mutagenicity profile of triclosan has been established from extensive postmarketing surveillance in dental and topical products. 20 Unlike antibiotics with a specific mode of action, its efficacy at "use" concentration remains unchanged given the multiple cellular targets of triclosan. 45, 46 The widespread use of triclosan for the past 35 years has not produced resistant strains that render it ineffective. 20, 47, 48 Nevertheless, there are theoretical risks that widespread use could potentially select triclosan-resistant strains that may exhibit cross-resistance to antibiotics. 47 Moreover, one trial has shown increased wound breakdown with triclosan-impregnated sutures in breast reduction surgery and, therefore, although cumulative analysis in this study has shown no adverse effects on wound breakdown, this endpoint should be continued to be monitored. There is an increasing recognition of the importance of evaluation of surgical innovations. [49] [50] [51] Unlike drug development, there is no established framework for pre-market appraisal of safety and efficacy of surgical innovations. Innovations that are substantially similar to previously approved devices are not subjected to rigorous assessment and are often fast-tracked into the market. 49 The absence of demonstrable benefit of these sutures-which are more closely related to a drug than most other surgical innovations-emphasizes the inappropriateness of such an approach and supports the need of high quality, prospective trials before such innovation are adopted into practice.
Because individual trials may be underpowered, meta-analysis, despite its limitations, is useful in this circumstance as it provides estimates with narrower CIs and greater statistical power. [52] [53] [54] As such, the pooled estimate from the included trials of moderate quality, including unpublished trials, provides the best evidence at present concerning the use of these sutures. The inclusion of gray literature has also overcome potential publication bias, thus increasing the validity of the findings. One of the included trials measured the incidence of cerebrospinal fluid shunt infection, but this was considered to be a suitable proxy for wound infection given that these shunts are a closed system. 29 The exclusion of this study in sensitivity analysis for the 2 outcomes did not alter the final results.
In the absence of clear benefit, it is not currently possible to recommend the routine use of triclosan-impregnated sutures. As such, the estimated 40% increase in cost incurred from the use of these cannot be justified. 42 Current use may be limited to the setting of a clinical trial for further investigation. For a relative risk reduction of 0.5 for SSIs with an α of 0.05 and β of 0.8, 552 patients would be required for an adequately powered trial if the incidence of SSIs is 16%. 55 This may lead to a role in the future where these sutures may be preferred in circumstances where the risk of SSI is deemed high such as contaminated wounds or where the consequences of SSI are catastrophic-for example, orthopedic or neurosurgical procedures.
In conclusion, triclosan-impregnated sutures have not been shown to reduce the rate of SSIs. They do not seem to adversely affect wound healing and further trials are required to identify specific clinical benefit. 
